Journal
CLINICAL INFECTIOUS DISEASES
Volume 50, Issue -, Pages S37-S44Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/648963
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases [K24 AI52788]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI052788] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Neisseria meningitidis is a leading cause of bacterial meningitis and other serious infections worldwide. The epidemiological profile of N. meningitidis is highly changeable, with great differences in disease incidence and serogroup distribution. Six serogroups (namely serogroups A, B, C, W-135, X, and Y) are responsible for most cases of meningococcal disease worldwide; the epidemiological profile of disease caused by each serogroup is unique. No vaccine is available for endemic disease caused by serogroup B strains. Two tetravalent (A/C/Y/W-135) meningococcal vaccines are licensed in the United States: a purified polysaccharide product and a polysaccharide-protein conjugate vaccine. The conjugate vaccine is recommended for all adolescents, although vaccine coverage remains low, and other groups at high risk of infection. A comprehensive program to prevent invasive meningococcal disease in the United States will require vaccination of infants; several conjugate vaccines for infants may become available in the near future. Broadly protective vaccines for endemic serogroup B disease are also needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available